Hjem › Neuroblastom › Californien
Neuroblastom kliniske forsøg i Californien
14 studier for Neuroblastom søger deltagere på steder i Californien.
Byer i Californien
- San Francisco7 studier
- Los Angeles7 studier
- Mountain View5 studier
- Oakland5 studier
- San Diego5 studier
- Orange3 studier
Officiel studietekst (engelsk)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- og 13 flere
RekruttererFase 3
Op til 30 år · Alle køn · Opdateret 2. okt. 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- University of California, San Francisco, San Francisco
Rekrutterer
Alle aldre · Alle køn · Opdateret 1. okt. 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RekruttererFase 2
Op til 22 år · Alle køn · Opdateret 4. sep. 2026 · NCT02559778Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RekruttererFase 1/2
Op til 30 år · Alle køn · Opdateret 3. sep. 2026 · NCT06541262Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Children's Hospital Los Angeles, Los Angeles
- og 9 flere
RekruttererFase 3
365 Days – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital of Orange County, Orange
- UCSF Medical Center-Mission Bay, San Francisco
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RekruttererFase 2
12 Months – 21 Years · Alle køn · Opdateret 12. aug. 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Stanford University, Palo Alto
RekruttererFase 1/2
Alder 2 til 21 · Alle køn · Opdateret 11. aug. 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
RekruttererFase 1/2
Alder 1 til 30 · Alle køn · Opdateret 22. jul. 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital, San Francisco
RekruttererFase 2
Alder 1 til 31 · Alle køn · Opdateret 20. jul. 2026 · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 19. maj 2026 · NCT04901702Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
- Stanford University, Palo Alto
RekruttererFase 1
Alder 2 til 30 · Alle køn · Opdateret 7. maj 2026 · NCT06500819Neuroblastoma Biology Study
- Children's Hospital Los Angeles, Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RekruttererObservationsstudie
31 Days – 99 Years · Alle køn · Opdateret 23. mar. 2026 · NCT01587300Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.